Koers Aastrom Biosciences Inc Nasdaq
Aandelen
US00253U3059
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | 239 mln. 224 mln. | Omzet 2025 * | 299 mln. 280 mln. | Marktkapitalisatie | 2,22 mld. 2,08 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 4 mln. 3,74 mln. | Nettowinst (verlies) 2025 * | 25 mln. 23,38 mln. | EV/omzet 2024 * | 9,3 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 7,43 x |
K/w-verhouding 2024 * |
576
x | K/w-verhouding 2025 * |
94,6
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,16% |
Recentste transcriptie over Aastrom Biosciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 60 | 01-03-13 | |
Joseph Mara
DFI | Director of Finance/CFO | 49 | 25-01-21 |
Michael Halpin
COO | Chief Operating Officer | 62 | 10-04-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Wotton
BRD | Director/Board Member | 63 | 06-01-15 |
Kevin McLaughlin
BRD | Director/Board Member | 67 | 06-01-15 |
Robert Zerbe
CHM | Chairman | 73 | 16-01-06 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-4,66% | 86,13 mld. | |
+1,32% | 39,82 mld. | |
-19,27% | 30,42 mld. | |
+57,86% | 25,23 mld. | |
-16,09% | 15,35 mld. | |
-9,14% | 11,95 mld. | |
-17,69% | 11,6 mld. | |
-43,00% | 11,51 mld. | |
+5,24% | 8,71 mld. |
- Beurs
- Aandelen
- Koers VCEL
- Koers